Cell and gene therapy platform company, Locate Bio, has announced that it is set to receive key patents for its IntraStem technology covering the United States and Europe
Cell and gene therapy platform company, Locate Bio, has announced that it is set to receive key patents for its IntraStem technology covering the United States and Europe, in a Jan. 7, 2019 press release.
IntraStem is a non-viral gene delivery technology that is based on cell penetrating peptides. The intracellular delivery system has been designed to overcome the limitations of current gene therapy vectors. Additionally, as a next-generation approach, the system is capable of delivering a variety of biologics, such as plasmid DNA, mRNA, siRNA, proteins, and antibodies, in various cell types, including hard-to-transfect cells.
“The granting of our first IntraStem patents in the US and Europe adds to the excitement building around our next generation, non-viral transfection technology,” commented Nick Staples, CEO of Locate, in a Jan. 7, 2019 press release. “We are delighted with the comparative performance of IntraStem versus current transfection standards, which has now extended across a wide range of cell types, payloads, and preclinical models. The broad utility of IntraStem opens up a multitude of therapeutic opportunities, including gene editing and cell reprogramming in-vivo. We are presently evaluating new product opportunities in therapy areas where cell and gene therapies may deliver breakthrough and potentially curative benefits to patients."
Source: Locate Bio
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.